Neumora Therapeutics Inc. (NASDAQ: NMRA)’s stock price has gone decline by -1.32 in comparison to its previous close of 9.10, however, the company has experienced a -0.88% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-16 that The FDA places a clinical hold on Neumora’s (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
Is It Worth Investing in Neumora Therapeutics Inc. (NASDAQ: NMRA) Right Now?
Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NMRA is 53.21M, and at present, short sellers hold a 11.03% of that float. On May 02, 2024, the average trading volume of NMRA was 581.31K shares.
NMRA’s Market Performance
NMRA’s stock has seen a -0.88% decrease for the week, with a -32.48% drop in the past month and a -41.11% fall in the past quarter. The volatility ratio for the week is 6.76%, and the volatility levels for the past 30 days are at 7.42% for Neumora Therapeutics Inc. The simple moving average for the past 20 days is -21.59% for NMRA’s stock, with a -34.53% simple moving average for the past 200 days.
Analysts’ Opinion of NMRA
Many brokerage firms have already submitted their reports for NMRA stocks, with Deutsche Bank repeating the rating for NMRA by listing it as a “Hold.” The predicted price for NMRA in the upcoming period, according to Deutsche Bank is $13 based on the research report published on December 12, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $26. The rating they have provided for NMRA stocks is “Outperform” according to the report published on October 10th, 2023.
Stifel gave a rating of “Buy” to NMRA, setting the target price at $26 in the report published on October 10th of the previous year.
NMRA Trading at -36.58% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.24% of loss for the given period.
Volatility was left at 7.42%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares sank -34.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.25% lower at present.
During the last 5 trading sessions, NMRA fell by -1.21%, in comparison to the 20-day moving average, which settled at $11.21. In addition, Neumora Therapeutics Inc. saw -47.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Burow Kristina, who purchase 3,357 shares at the price of $11.98 back on Nov 14 ’23. After this action, Burow Kristina now owns 4,131,207 shares of Neumora Therapeutics Inc., valued at $40,217 using the latest closing price.
ARCH Venture Partners XII, LLC, the 10% Owner of Neumora Therapeutics Inc., purchase 3,357 shares at $11.98 during a trade that took place back on Nov 14 ’23, which means that ARCH Venture Partners XII, LLC is holding 4,131,207 shares at $40,217 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.43. Equity return is now at value -54.49, with -51.15 for asset returns.
Based on Neumora Therapeutics Inc. (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -24.77.
Currently, EBITDA for the company is -135.28 million with net debt to EBITDA at 1.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.05.
Conclusion
To sum up, Neumora Therapeutics Inc. (NMRA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
